VOR BIOPHARMA INC (VOR) Stock News
NASDAQ:VOR - Nasdaq - US9290331084 - Common Stock - Currency: USD
VOR Latest News, Press Relases and Analysis
This International Paper Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
VOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024
VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the second quarter of 2024.
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that,...
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate...
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the...
Vor Bio Announces $55.6 Million Private Placement
Vor Bio Announces $55.6 Million Private Placement
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a...
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse...
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the...
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker...
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...
Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
On-track for trem-cel + Mylotarg™ and VCAR33ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that,...